UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
December 28, 2005
(Date of report)
CARACO PHARMACEUTICAL
LABORATORIES, LTD.
(Exact name of registrant as
specified in its charter)
| Michigan
(State or other jurisdiction of incorporation) |
0-24676 (Commission file number) |
38-2505723
(I.R.S. employer identification no.) |
1150 Elijah McCoy
Drive, Detroit, Michigan 48202
(Address of
principal executive offices)
(313) 871-8400
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |_| | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |_| | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12) |
| |_| | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |_| | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On December 27, 2005, the U.S. Food and Drug Administration granted tentative approval of the Company’s ANDA for Carvedilol 3.125 mg tablets. Final approval of this product is anticipated subsequent to the expiry of patent protection in February 2016. Caraco’s Carvedilol 3.125 mg tablets is the generic equivalent of GlaxoSmithkline’s Coreg® 3.125mg, which is indicated for the treatment of mild to severe heart failure of ischemic or cardiomyopathic origin. It is also indicated to reduce cardiovascular mortality and for the management of essential hypertension.
Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: December 29, 2005 | By: /s/
Daniel H. Movens ————————————————— Daniel H. Movens Chief Executive Officer |